Monitoring blood clotting risk after donor stem cell transplant
Part of Blood & lymphatic clinical trials.
This study tracks patients who receive a stem cell transplant from a donor to see how often they develop a blood condition called transplant-associated thrombotic microangiopathy (TA-TMA). The goal is to identify patients at higher risk and monitor them closely for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must be scheduled for a stem cell transplant from a donor.
- You must have certain risk factors (like high BMI, a mismatched donor, a non-cancer blood disease, a certain type of leukemia, certain ethnic backgrounds, strong chemo, kidney problems, radiation, or a previous transplant) — OR you may have graft-versus-host disease (GVHD) that is severe or not responding to treatment.
- If you are able to become pregnant, you must have a negative pregnancy test before joining.
- You should not have another active cancer that is being treated or that limits your life expectancy.
- You must be able to follow the study requirements and not have psychiatric or social issues that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at how two immune system proteins, interferon and complement, are involved in a rare condition called thrombotic microangiopathy (TMA) that can damage small blood vessels after a stem cell or organ transplant. Understanding these proteins may help doctors find better treatments for TMA and related complications.
Hear when a new Transplant Complication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.